<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786603</url>
  </required_header>
  <id_info>
    <org_study_id>12312</org_study_id>
    <secondary_id>R01FD003739</secondary_id>
    <nct_id>NCT01786603</nct_id>
  </id_info>
  <brief_title>Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Richard Barohn, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons
      in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and
      loss of muscle function. Motor neurons are responsible for sending signals to muscles in our
      bodies to trigger movement. While there are drugs to help relieve symptoms of ALS, there is
      no cure for ALS.

      Rasagiline is a drug with possible neuroprotective characteristics. Neuroprotective means
      that the nervous system may be protected against weakening. It is known that rasagiline has
      possible neuroprotective characteristics, but the effectiveness of rasagiline for patients
      with ALS has not been tested. Rasagiline is approved for the treatment of Parkinson's
      disease.

      Rasagiline for treatment of ALS is not approved by the U.S. Food and Drug Administration
      (FDA) and is investigational. Investigational drugs are studied to find out if they are safe
      and effective in the treatment of diseases or conditions.

      By doing this study, researchers hope to learn if rasagiline is safe and slows disease
      progression in patients with ALS.

      Funding Source - FDA OOPD (FDA Orphan Products Division).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a phase II, double-blind, placebo-controlled, multicenter study of rasagiline
      2mg/day. Subjects will be assigned to either active agent or placebo (3:1) for twelve months.
      Subjects will undergo outpatient evaluations at screening, baseline, and months 1, 2, 4, 6,
      8, 10 and 12 and telephone assessments at months 3, 5, 7 and 9. There will be a close-out
      phone call 30 days post month 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2013</start_date>
  <completion_date type="Actual">July 27, 2016</completion_date>
  <primary_completion_date type="Actual">July 27, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALS Functional Rating Scale-Revised (ALSFRS-R)</measure>
    <time_frame>ALS Functional Rating Scale-Revised (ALSFRS-R) Difference from Baseline to Month 12</time_frame>
    <description>Difference in ALS Functional Rating Scale - Revised (ALSFRS-R) score. The ALSFRS-R is an ordinal rating scale that assesses 12 functional activities. Each activity is scored between 0-4, with a total score ranging from 48 (normal function) to 0 (no function).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vital Capacity (VC)</measure>
    <time_frame>Vital Capacity Change from Baseline to Month 12</time_frame>
    <description>Determine if decline in vital capacity is slower in participants taking 2 mg rasagiline than controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Quality of Life Change from Baseline to Month 12</time_frame>
    <description>Participants completed the single-item ALSQOL (ALS Quality of Life) which asks participants to rank their global quality of life, considering all parts of their lives - physical, emotional, social, spiritual and financial - in the last 7 days and rate on a scale of 0 (very bad) to 10 (excellent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Adverse Events from Baseline to Month 12</time_frame>
    <description>Determine if participants on rasagiline 2 mg had a different safety profile than patients not on rasagiline. Adverse event information to be collected from date of enrollment until end of study participation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Survival Status Between Study Groups</measure>
    <time_frame>Survival status at Month 12</time_frame>
    <description>Determine if there is a difference in survival between participants on rasagiline than patients not on rasagiline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Study Drug on Apoptosis Markers</measure>
    <time_frame>Apoptosis Marker change from Baseline to Month 12</time_frame>
    <description>Effect of rasagiline on the apoptosis markers (Annexin V stain) in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Study Drug on Oxidative Stress</measure>
    <time_frame>Oxidative Stress change from Baseline to Month 12</time_frame>
    <description>Determine if oxygen radical antioxidant capacity is targeted by rasagiline in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>Rasagiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <description>Rasagiline 2mg once a day for 12 months.</description>
    <arm_group_label>Rasagiline</arm_group_label>
    <other_name>Azilect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A clinical diagnosis of laboratory-supported probable, probable, or definite ALS,
             according to a modified El Escorial criteria, by the study investigator (Appendix IV).

          2. 21 to 80 years of age inclusive.

          3. VC greater or equal to 75% of predicted at screening and baseline.

          4. Onset of weakness within 2 years prior to enrollment.

          5. If patients are taking riluzole for ALS, they must be on a stable dose for at least
             thirty days prior to the baseline visit.

          6. Women of childbearing age must be non-lactating and surgically sterile or using an
             effective method of birth control and have a negative pregnancy test.

          7. Willing and able to give signed informed consent that has been approved by the
             Institutional Review Board (IRB).

        Exclusion criteria

          1. Requirement for tracheotomy ventilation or non-invasive ventilation for &gt; 23 hours per
             day.

          2. Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine,
             phenylpropanolamine, and ephedrine.

          3. Patients on analgesics with serotoninergic properties such as meperidine, tramadol,
             methadone and propoxyphene, flexeril.

          4. Patients on fluoxetine or fluvoxamine.

          5. Patients taking amitriptyline &gt; 50 mg/d, trazodone and sertraline &gt; 100 mg/d,
             citalopram &gt; 20 mg/d or paroxetine &gt; 30 mg/d.

          6. Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease,
             etc).

          7. Clinically significant history of unstable medical illness (unstable angina, advanced
             cancer, etc) over the last 30 days.

          8. Has a diaphragm pacing device or plan on obtaining a diaphragm pacing device during
             the course of the study.

          9. History of renal disease.

         10. History of liver disease.

         11. Current pregnancy or lactation.

         12. Limited mental capacity such that the patient cannot provide written informed consent
             or comply with evaluation procedures.

         13. History of recent alcohol or drug abuse or noncompliance with treatment or other
             experimental protocols.

         14. Vital Capacity (VC) &lt; 75% of predicted.

         15. Receipt of any investigational drug within the past 30 days.

         16. Women with the potential to become pregnant who are not practicing effective birth
             control.

         17. Poorly controlled hypertensive subjects or resting systolic blood pressure (SBP) &gt; 160
             mmHg and/or diastolic (DBP) &gt; 95 mmHg.

         18. Use of BiPAP at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Barohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Neurological Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <results_first_submitted>October 15, 2019</results_first_submitted>
  <results_first_submitted_qc>January 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Richard Barohn, MD</investigator_full_name>
    <investigator_title>Gertrude and Dewey Zeigler Professor of Neurology and Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rasagiline</title>
          <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician decision to withdraw</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rasagiline</title>
          <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="10.2"/>
                    <measurement group_id="B2" value="57.5" spread="8.5"/>
                    <measurement group_id="B3" value="57.95" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ALS Functional Rating Scale-Revised (ALSFRS-R)</title>
        <description>Difference in ALS Functional Rating Scale - Revised (ALSFRS-R) score. The ALSFRS-R is an ordinal rating scale that assesses 12 functional activities. Each activity is scored between 0-4, with a total score ranging from 48 (normal function) to 0 (no function).</description>
        <time_frame>ALS Functional Rating Scale-Revised (ALSFRS-R) Difference from Baseline to Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>ALS Functional Rating Scale-Revised (ALSFRS-R)</title>
          <description>Difference in ALS Functional Rating Scale - Revised (ALSFRS-R) score. The ALSFRS-R is an ordinal rating scale that assesses 12 functional activities. Each activity is scored between 0-4, with a total score ranging from 48 (normal function) to 0 (no function).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-1.22" upper_limit="-0.77"/>
                    <measurement group_id="O2" value="-1.26" lower_limit="-1.64" upper_limit="-0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vital Capacity (VC)</title>
        <description>Determine if decline in vital capacity is slower in participants taking 2 mg rasagiline than controls.</description>
        <time_frame>Vital Capacity Change from Baseline to Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vital Capacity (VC)</title>
          <description>Determine if decline in vital capacity is slower in participants taking 2 mg rasagiline than controls.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" lower_limit="-2.86" upper_limit="-1.64"/>
                    <measurement group_id="O2" value="-2.48" lower_limit="-3.54" upper_limit="-1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life</title>
        <description>Participants completed the single-item ALSQOL (ALS Quality of Life) which asks participants to rank their global quality of life, considering all parts of their lives - physical, emotional, social, spiritual and financial - in the last 7 days and rate on a scale of 0 (very bad) to 10 (excellent).</description>
        <time_frame>Quality of Life Change from Baseline to Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life</title>
          <description>Participants completed the single-item ALSQOL (ALS Quality of Life) which asks participants to rank their global quality of life, considering all parts of their lives - physical, emotional, social, spiritual and financial - in the last 7 days and rate on a scale of 0 (very bad) to 10 (excellent).</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" lower_limit="-0.13" upper_limit="-0.06"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-0.18" upper_limit="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Determine if participants on rasagiline 2 mg had a different safety profile than patients not on rasagiline. Adverse event information to be collected from date of enrollment until end of study participation.</description>
        <time_frame>Adverse Events from Baseline to Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Determine if participants on rasagiline 2 mg had a different safety profile than patients not on rasagiline. Adverse event information to be collected from date of enrollment until end of study participation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Survival Status Between Study Groups</title>
        <description>Determine if there is a difference in survival between participants on rasagiline than patients not on rasagiline</description>
        <time_frame>Survival status at Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Survival Status Between Study Groups</title>
          <description>Determine if there is a difference in survival between participants on rasagiline than patients not on rasagiline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Study Drug on Apoptosis Markers</title>
        <description>Effect of rasagiline on the apoptosis markers (Annexin V stain) in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.</description>
        <time_frame>Apoptosis Marker change from Baseline to Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Study Drug on Apoptosis Markers</title>
          <description>Effect of rasagiline on the apoptosis markers (Annexin V stain) in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.023"/>
                    <measurement group_id="O2" value="0.02" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Study Drug on Oxidative Stress</title>
        <description>Determine if oxygen radical antioxidant capacity is targeted by rasagiline in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.</description>
        <time_frame>Oxidative Stress change from Baseline to Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Study Drug on Oxidative Stress</title>
          <description>Determine if oxygen radical antioxidant capacity is targeted by rasagiline in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.</description>
          <units>pmole/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.73"/>
                    <measurement group_id="O2" value="1.21" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rasagiline</title>
          <description>Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline: Rasagiline 2mg once a day for 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Laboratory Abnormality</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and Labyrinth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="49" subjects_affected="22" subjects_at_risk="60"/>
                <counts group_id="E2" events="21" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, Poisoning, Procedural Complications</sub_title>
                <counts group_id="E1" events="25" subjects_affected="11" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E2" events="20" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="60"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical/Medical</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard Barohn</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-945-9944</phone>
      <email>rbarohn@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

